Aquinnah Pharmaceuticals Obtains $5,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=28d69f84-6a38-45b0-b505-ef3848a80e30 - Date
12/22/2015 - Company Name
Aquinnah Pharmaceuticals - Mailing Address
700 Main Street North Cambridge, MA 02139 USA - Company Description
Aquinnah Pharmaceutical’s approach is unique by integrating human genetic, human pathology and cellular biology R&D expertise, towards the development of a new therapeutic approach. Our approach has the potential to treat the majority of patients with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease. - Website
http://www.aquinnahpharma.com - Transaction Type
Venture Equity - Transaction Amount
$5,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
This funding adds further momentum to the numerous peer reviewed grants that we have received and will accelerate our program toward clinical development of new drugs for ALS and other neurodegenerative diseases. - M&A Terms
- Venture Investor
Takeda Ventures
